{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dabigatran+%28Pradaxa%29&page=2",
    "query": {
      "intervention": "Dabigatran (Pradaxa)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 94,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dabigatran+%28Pradaxa%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dabigatran+%28Pradaxa%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T12:14:56.375Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01852162",
      "title": "Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "Dabigatran",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 35,
      "start_date": "2012-02",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2015-03-17",
      "last_synced_at": "2026-10-07T12:14:56.375Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01852162"
    },
    {
      "nct_id": "NCT03006341",
      "title": "Validation of Predictors of OAC Initiation Using EMR Data",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Dabigatran etexilate",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140187,
      "start_date": "2017-02-28",
      "completion_date": "2017-05-09",
      "has_results": true,
      "last_update_posted_date": "2019-03-22",
      "last_synced_at": "2026-10-07T12:14:56.375Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03006341"
    },
    {
      "nct_id": "NCT02149303",
      "title": "Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation",
        "Hemorrhage"
      ],
      "interventions": [
        {
          "name": "Dabigatran 75 mg",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran 150 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 191,
      "start_date": "2014-06",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-04-04",
      "last_synced_at": "2026-10-07T12:14:56.375Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Brooklyn, New York • Stony Brook, New York + 1 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02149303"
    },
    {
      "nct_id": "NCT03520868",
      "title": "Heparin Requirements in Patients Undergoing Atrial Fibrillation Ablation on Coumadin vs NOACs",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Monitoring Anti Factor Xa level",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Steward St. Elizabeth's Medical Center of Boston, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2017-05-05",
      "completion_date": "2020-03-30",
      "has_results": false,
      "last_update_posted_date": "2021-07-16",
      "last_synced_at": "2026-10-07T12:14:56.375Z",
      "location_count": 1,
      "location_summary": "Brighton, Massachusetts",
      "locations": [
        {
          "city": "Brighton",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03520868"
    },
    {
      "nct_id": "NCT04192916",
      "title": "Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myeloproliferative Neoplasm"
      ],
      "interventions": [
        {
          "name": "DOACs",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 442,
      "start_date": "2019-09-01",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-10-07T12:14:56.375Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04192916"
    },
    {
      "nct_id": "NCT02022020",
      "title": "Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 220,
      "start_date": "2014-01",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-01-31",
      "last_synced_at": "2026-10-07T12:14:56.375Z",
      "location_count": 16,
      "location_summary": "Aurora, Colorado • New Britain, Connecticut • Orlando, Florida + 13 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Britain",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02022020"
    },
    {
      "nct_id": "NCT06533280",
      "title": "VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Part A, C and D: VH3739937 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Part A: VH3739937 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Part A and C: Placebo",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment A",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment B",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment C",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment D",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment E",
          "type": "DRUG"
        },
        {
          "name": "Part D: Probe cocktail",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-08-02",
      "completion_date": "2024-08-14",
      "has_results": false,
      "last_update_posted_date": "2025-04-22",
      "last_synced_at": "2026-10-07T12:14:56.375Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06533280"
    },
    {
      "nct_id": "NCT06957366",
      "title": "Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Atrial Fibrillation (AF)",
        "VTE"
      ],
      "interventions": [
        {
          "name": "PAUSE Perioperative DOAC Management",
          "type": "OTHER"
        },
        {
          "name": "ASRA Perioperative DOAC Management",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "McMaster University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 920,
      "start_date": "2025-04-01",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-05-09",
      "last_synced_at": "2026-10-07T12:14:56.375Z",
      "location_count": 6,
      "location_summary": "Hartford, Connecticut • Evanston, Illinois • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06957366"
    },
    {
      "nct_id": "NCT00680186",
      "title": "Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Warfarin",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran etexilate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2589,
      "start_date": "2008-04",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-05-19",
      "last_synced_at": "2026-10-07T12:14:56.375Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Clearwater, Florida • Normal, Illinois + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Normal",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Stony Brook",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00680186"
    },
    {
      "nct_id": "NCT07190430",
      "title": "A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "PF-08049820",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran Etexilate",
          "type": "DRUG"
        },
        {
          "name": "Portia (EE and LN) or equivalent oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 16,
      "start_date": "2025-10-03",
      "completion_date": "2025-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-07T12:14:56.375Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07190430"
    }
  ]
}